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Abstract
It is recognised that new scientiﬁc improvements and their integration in risk assessment, as outlined
in the National Academies of Sciences, Engineering and Medicine 2017 report, have the potential to
improve human health risk assessments by enabling a mechanistic understanding of adverse effects
and more accurate predictions of biological responses. Here, I discuss why such improvements are
needed and can ease a paradigm shift in human health risk assessment. The current approach to
human health risk assessment is limited by several elements: (1) the relevance of data is debatable, as
they are largely based on in vivo animal models that are poorly predictive for complex endpoints, raise
challenges with regard to interspecies extrapolations, and are seldom informative of the mechanism
underlying the observed effects; (2) lack of ﬂexibility in data requirements by regulators, which limits
the uptake of new scientiﬁc developments in a timely manner; and (3) lack of data accessibility, which
makes data integration difﬁcult. However, mechanistic-based assessments are currently conducted for
the identiﬁcation of endocrine disruptors and are developed for addressing developmental
neurotoxicity. Such assessments can serve as examples for changing the paradigm of risk assessment.
There are several opportunities for improvement, such as: make regulatory standard requirements less
prescriptive; enhance and use the opportunities for read-across; analyse and quantify uncertainties in
order to benchmark new approach methods to the current system; better integrate screening methods
early in regulatory assessments and decision-making; and develop more adverse outcome pathways in
order to link new approach methods with the current approach and ultimately make it possible to base
regulatory decisions on early key events of a toxicity pathway.
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1. Introduction
In the 2017 report from the National Academies of Sciences, Engineering, and Medicine, ‘Using 21st
century science to improve risk-related evaluations’, recommendations are provided on how to
integrate the latest scientiﬁc and technological advances in toxicology, exposure science and
epidemiology in human health risk assessments and improve risk-related evaluations (NASEM, 2017).
These new tools enable a mechanistic understanding of adverse effects and more accurate predictions
of biological responses; in other words, they help to establish causality. Mechanistic information can be
obtained through the development and evaluation of alternative methods combining non-animal
in vitro and in silico methods (‘new approach methods’, NAMs). Likewise, epidemiological research is
undergoing a transition from empirical observations alone to a focus on the underlying biology. This
type of evidence should also be better integrated into risk assessment.
So, there is consensus that the above-mentioned developments have the potential to improve risk
assessments and the NASEM report recommends a holistic approach for future chemical risk
assessments; holistic in terms of integrating different streams of evidence covering both hazard and
exposure data. However, it remains to be seen whether the current EU regulatory framework is
sufﬁciently ﬂexible to fully realise the beneﬁts of more holistic human health risk assessments as the
current risk assessment framework is highly compartmentalised. Compartments occur at different
levels:
• Successive steps of the risk assessment process (i.e. hazard identiﬁcation, hazard
characterisation, exposure characterisation and risk assessment).
• Compound-based assessments. Typically, each compound is assessed separately. Only data on
the compound under evaluation are utilised, while information on closely related compounds
are not necessarily considered on a routine basis.
• Regulatory siloes, e.g. registration, evaluation, authorisation and restriction of chemicals
(REACH), pesticide regulations, biocide regulations, medicines, food ﬂavourings, etc. The
consequence is that the same compounds and data sets are being assessed in different
contexts at different times with different approaches, which can result in different assessment
outcomes (no-observed-adverse-effect levels (NOAELs) of studies, reference values, etc.).
In determining whether the current regulatory framework supports a holistic approach to human
health risk assessment, one needs to recognise these different compartments and the extent to which
they currently hamper a holistic approach for chemical risk assessment.
Here, I discuss the EU regulatory systems for chemical risk assessment in relation to human risk
assessment, focusing on pesticide regulation,1 and whether it is ﬁt and adequately agile to incorporate
new advancements in toxicology, exposure science and epidemiology.
2. The current system
2.1. The compartmentalisation in the current risk assessment approach
The current approach for chemical risk assessment in Europe is deﬁned by different regulations,
e.g. for cosmetics, food contact materials and pesticides. To achieve their protection goals, they deﬁne
which data are necessary to conduct the risk assessment with a reasonable level of conﬁdence. These
data requirements to a certain extent reﬂect a perceived assumption regarding risks. For example, in
REACH, the standard requirements are deﬁned by tonnage. This allows a rough estimate of exposure;
for production volumes of under 1 tonne, far fewer data are required than for tonnages over 100.
For pesticides (except biopesticides and low-risk pesticides), data requirements are according to the
concept ‘one-size-ﬁts-all’, thus regardless of the intended use, i.e. exposure and risk. The same data
are required for each single substance. Yet, the data requirements for pesticides are vast (see Table 1)
addressing acute to repeat-dose/chronic exposure, speciﬁc effects on reproduction, neurotoxicity and
in some instances toxicological mode of action, and are mostly based on animal studies.
Moreover, the studies required should be conducted in compliance with OECD guidelines for the
testing of chemicals or equivalent (for example, guidelines of the Ofﬁce of the Pesticide Program, US
Environmental Protection Agency). The guidelines specify how the test should be conducted and what
examinations should be performed, with a vast set of in vivo and post mortem analyses performed.
1 Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 October 2009 concerning the placing of
plant protection products on the market and repealing Council Directives 79/117/EEC and 91/414/EEC. OJ L 309, 24.11.2009,
p. 1–50.
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Typically, all tissues should be examined macro- and microscopically. Clinical chemistry parameters
should be measured as well as food and water intake, and clinical signs should be monitored.
When data from all these studies are compiled, there are literally several thousand data entries for
each single substance that identify and characterise the hazards.
For pesticides in the EU as well as for other chemicals regulated under other jurisdictions, data
requirements are to a large extent (or even fully) prescriptive. That is, under the current system, the
data requirement is prescriptive and centred on single substances, with no use of knowledge from
similar substances to waive speciﬁc data, investigations or studies.
Moreover, the required data are only descriptive: the OECD test guidelines are designed to detect
and characterise hazards through descriptive observations of effects, and not to understand
mechanisms. Therefore, data requirements for the risk assessment of pesticides do not necessarily
provide a mechanistic understanding of observed toxicities. Finally, the data always describe the
effects in a model species, often a rodent. Yet, there is uncertainty around extrapolations from model
species to humans for many observed effects, some of which are not well explained and not well
quantiﬁed (WHO, 2017).
In conclusion, the current EU regulatory framework is to a large extent prescriptive and requires
mandatory in vivo tests, without the possibility to waive such requirements on a scientiﬁc, case-by-
case basis (unless it is already known that the compound has certain properties, e.g. being a
carcinogen). Since in vivo experiments are still compulsory, the current system does not speciﬁcally
promote the generation and integration of 21st century toxicity data into chemical risk assessments.
Only in the rare cases where the petitioner proposes a claim on for example the non-human relevance
of an effect, is there in reality an incentive to generate mode of action data and data on the
differences between species.
2.2. Strengths, weaknesses, opportunities and threats of the current
risk assessment system
There is conﬁdence in the current system. After all, for many regulated chemicals on a single
substance basis, there is no strong evidence of lack of safety pertaining to their use so far. However,
the current system does not allow us to tell how safe the use of a compound is due to the following
Table 1: Data requirement of pesticidal active substances according to EU Regulation 283/2013(a) –
Setting data requirements for active substances. These data must be submitted, unless
the substance is a low risk substance or a biopesticide
Data requirements – pesticidal active substances
Toxicokinetics – absorption, distribution, excretion, metabolism – single and repeated dose rat
Acute exposure – oral, dermal, inhalation rat
Irritation – eye, skin rabbit
Sensitisation mouse
Subchronic toxicity (28–90 days) rat
Subchronic toxicity (28 days – 1 year) dog
Genotoxicity – in vitro (mutagenicity, chromosome aberrations, aneugenicity)
Genotoxicity – in vivo (chromosome aberrations – possibly others) mouse
Chronic toxicity (2 year) rat
Carcinogenicity (2 year) rat
Carcinogenicity mouse
Teratogenicity rat
Teratogenicity rabbit
Reproduction – 1 or 2 generations rat
Neurotoxicity (acute and/or chronic exposure) rat, developmental neurotoxicity rat
All relevant data from open literature (systematic review)
Others – e.g. studies on endocrine modes of actions
(a): Commission Regulation (EU) No 283/2013 of 1 March 2013 setting out the data requirements for active substances, in
accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of
plant protection products on the market. OJ L 93, 3.4.2013, p. 1–84.
Holistic approach for human health risk assessment
www.efsa.europa.eu/efsajournal 5 EFSA Journal 2019;17(S1):e170711
factors. Risk assessments as currently conducted: (1) rely heavily on non-human data; (2) are based
on in vivo data, which are not designed to provide mechanistic understanding; (3) do not cover
multifactorial disease aetiologies; (4) do not consider co-exposures; (5) rely on reference doses
derived from NOAELs that do not enable a quantiﬁcation of the uncertainty; and (6) rely on ill-deﬁned
protection goals.
The current risk assessment system is based on a wide range of tests that aim to determine that
there are no observed adverse effect levels per compound, with reference values that should cover
vulnerable groups. Reasonable upper exposure limits are estimated for the levels of human exposure
to the compound. Finally, risk assessments are carried out for relevant populations.
However, it remains possible that some adverse effects in humans are not predicted accurately by
regulatory toxicity testing. Such effects may also remain undetected because current testing models do
not capture the disease, or epidemiological surveillance is insufﬁcient or insensitive. In particular,
doubts remain as to whether common and complex human health outcomes are appropriately covered
by current standard toxicity tests. Such concerns have been reported in different domains:
• Immunotoxicity, childhood leukaemias (EFSA PPR Panel, 2017a; Pelkonen et al., 2017).
• Developmental neurotoxicity (EFSA PPR Panel, 2013), chronic neurological diseases such as
Parkinson’s disease (EFSA PPR Panel, 2017b, Terron et al., 2018).
• Neuropsychological effects and mental illnesses, as well as endocrine disorders such as some
hormonal cancers, endometriosis, metabolic syndrome, type 2 diabetes, and reproductive
senescence (OECD, 2014a).
One of the strengths of the current chemical risk assessment system is that an extensive amount of
data has been gathered since the relevant regulations came into force. However, these data are to a
large extent descriptive in vivo data, with inherent limitations. In most cases, they provide no
mechanistic information, do not capture effects relevant for humans, and are poorly reproducible,
difﬁcult to interpret and insensitive (Olson et al., 2000; Leist et al., 2008; Basketter et al., 2012).
In contrast, the vast amount of data gathered under certain regulations (e.g. pesticide risk
assessment) offers the opportunity to utilise such data. However, the data are currently far from being
easily available and analysable even for risk assessors. Consequently, only a few assessors, based on
decades of personal experience, have a holistic overview. In fact, until recently, access to data has
only been possible upon speciﬁc access requests, without violating conﬁdentiality issues. With the
European Commission’s proposal for a new food law,2 all data would be made public proactively
(except data where conﬁdentiality can be claimed due to propriety reasons). This is of course a ﬁrst
step, but it is most likely that the data will be released in different formats, including those that are
not searchable. The data will not necessarily be made available in databases. This raises a signiﬁcant
challenge for external risk assessors and scientists that would like to analyse the full data sets, as
several thousand pages would have to be analysed for each compound to fully contextualise different
ﬁndings (given that knowledge of similar compounds is typically also taken into account in market
registration applications for chemical stressors).
In order to make better use of data, they must be collected, curated, annotated and inserted into
an open database. In the area of human medicine, this is exactly what is currently under development
with the Innovative Medicines Initiatives projects eTOX3 and eTransafe.4 The overall aim of these
databases is to predict safety issues in silico (i.e. using computer models) by learning from companies’
existing pre-clinical data.
It is obvious that having detailed prescriptive and mandatory data requirements is not geared
towards fast-evolving scientiﬁc developments; the experience gained in changing mandatory data
requirements shows that this is a lengthy process as various parliamentary and legal processes are
2 Proposal for a Regulation of the European Parliament and of the Council on the transparency and sustainability of the EU risk
assessment in the food chain amending Regulation (EC) No 178/2002 [on general food law], Directive 2001/18/EC [on the
deliberate release into the environment of GMOs], Regulation (EC) No 1829/2003 [on GM food and feed], Regulation (EC)
No 1831/2003 [on feed additives], Regulation (EC) No 2065/2003 [on smoke ﬂavourings], Regulation (EC) No 1935/2004 [on
food contact materials], Regulation (EC) No 1331/2008 [on the common authorisation procedure for food additives, food
enzymes and food ﬂavourings], Regulation (EC) No 1107/2009 [on plant protection products] and Regulation (EU) No 2015/
2283 [on novel foods]. COM/2018/0179 ﬁnal – 2018/088 (COD) (https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=
1523604766591&uri=COM:2018:179:FIN).
3 http://www.etoxproject.eu/
4 http://etransafe.eu/
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involved. The inertia of the system is clearly a threat to conducting a risk assessment that lives up to
current scientiﬁc standards.
On the other hand, more ﬂexibility cannot come at the expense of safety. To be accepted by
regulatory bodies, NAMs need to be adequately annotated, described and their performance shown to
be, for example, in accordance with OECD guidance 211 on non-guideline in vitro methods (OECD,
2014b) and OECD guidance 286 on good in vitro practices (OECD, 2018).
3. Moving towards a holistic approach for human health risk
assessments
3.1.1. Read-across
Currently, as recognised in several analyses on applying 21st century science and technologies to
chemical risk assessment, no NAMs can fully and easily replace, for example, a 90-day feeding study
with rodents (NASEM, 2017; SAPEA, 2018). However, exploring and utilising grouping and read-across
better than is currently practised would be a ﬁrst step towards the integration of NAMs into risk
assessment.
In the EU, a number of different regulations allow the use of read-across. Under EFSA’s remit, read-
across has been used in the areas of chemical contaminants, food contact materials, feed, food
additives and ﬂavourings (Chesnut et al., 2018). Yet, there are notable exceptions, like the Pesticide
Regulation and associated data requirements. Basically, replacing mandatory studies with read-across
data is not mentioned explicitly in the Regulation. However, in a few relatively simple cases (for
example, read-across from a racemic mixture to an isomer), read-across data have replaced
mandatory studies. The recent regulation5 on identifying endocrine disruptors under the Pesticide
Regulation does not allow for read-across. However, the guidance implementing the criteria for
identifying the endocrine disruptors (ECHA/EFSA, 2018) mentions read-across and QSAR as types of
data that can be used for risk assessment purposes.
Read-across is mostly used to bridge data gaps, typically on complex endpoints such as toxicity
after repeated exposure to compounds or developmental and reproductive toxicity (ECHA, 2014).
Read-across requires a similarity assessment of the grouped compounds in terms of toxicokinetic and
dynamic properties. It is often a challenge to reach a conclusion on the similar adverse toxicological
effect pattern, as the apical ﬁndings might vary in the type, severity and lowest observed adverse
effect level within the grouped compounds (Judson et al., 2017). Another difﬁculty is that, apical
ﬁndings from in vivo data often do not enable a mechanistic understanding of the observed adverse
outcomes.
The use of NAMS in read-across and grouping sounds straightforward; however, it presents
practical challenges and at present and there are only a few examples of the successful integration of
NAMs in read-across (Ball et al., 2016). Different initiatives have been taken to make better use of
NAMs in risk assessment: the OECD with their case studies on an Integrated Approach to Testing and
Assessment (IATA) (OECD, online-a), and the US EPA with the GenRA tool (Generalised read-across)
(US EPA, online).
In the H2020-supported project, EU-ToxRisk,6 read-across approaches are used and developed to
integrate mechanistic knowledge (e.g. adverse outcome pathways, AOPs) in human hazard assessment
(Leist et al., 2017). One of the aims of the project is to illustrate with case studies how in vitro assays,
in silico studies (e.g. (quantitative) structural activity relationships ((Q)SAR) and/or physiology-based
toxicocokinetic (PBTK) models) together with AOPs can be used to prove (dis)similarity or a consistent
trend within a read-across assessment.
3.1.2. Adverse outcome pathways
The use of NAMs to underpin read-across arguments is an obvious possibility, and in the case of
read-across scenarios based on biological similarity rather than chemical similarity (which are by far
the most common), it would be crucial. Most obviously the argumentation would be based on a
mechanistic hypothesis like knowledge about AOPs (Leist et al., 2017).
5 Commission Regulation (EU) 2018/605 of 19 April 2018 amending Annex II to Regulation (EC) No 1107/2009 by setting out
scientiﬁc criteria for the determination of endocrine disrupting properties. OJ L 101, 20.4.2018, p. 33–36.
6 http://www.eu-toxrisk.eu/
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The concept of AOPs simpliﬁes a toxicological mechanism to a series of chemically agnostic
sequential events starting with a molecular initiation event, followed by key events and key event
relationships, which lead to cellular as well as organ responses and the ﬁnal adverse effect in the
organism (Leist et al., 2017). An AOP is seen as a useful tool to structure critical steps within a
complex biological process (Ankley et al., 2010). The key events are essential for the progression
towards the adverse outcome and can ideally be assessed by relevant in vitro and in silico models
(Villeneuve et al., 2014a,b; Ball et al., 2016). The vision is that regulatory decisions, like establishing
point of departure, can be based on early key events, surpassing the need for in vivo apical data.
Since the use of new assays and technologies for risk assessment purposes holds much promise,
anchoring these to AOPs in risk assessment is helpful. Therefore, to ensure regulatory acceptance,
development and review of AOPs is conducted under the auspices of the OECD (OECD, online-b). The
AOP-wiki is an open space where anyone can upload an AOP on the web page. Several hundreds of
AOPs can be found at very different levels of maturity. To become reviewed and fully endorsed by the
OECD Working Group of National Coordinators of the Test Guideline Programme an AOP must undergo
two review processes to ensure that the AOPs have followed the instructions and guidelines. This is a
lengthy process and at the moment only a few AOPs have undergone the whole procedure and a few
dozen more are going through the process.
However, efforts put into AOP development seem rather unbalanced compared with the efforts and
resources being put into developing all the new tools, assays, models and technologies, etc. This
probably has many explanations: (1) no speciﬁc resource allocation; (2) uncertainty of scientiﬁc
recognition, i.e. authorship on an AOP is often not being recognised academically; and (3) extensive
efforts are required similar to those for conducting a systematic review.
3.1.3. Open doors
Moving towards a holistic assessment from the current system is a huge challenge. However, there
are examples and areas where the transition will be more easily be accepted and implemented; this is
the case where the current system has recognised weaknesses or where there are already
requirements in the regulations regarding mechanistic understanding.
In other words, are there any doors already open?
The newly adopted regulation for identifying endocrine disruptors in the context of the pesticide
and biocide risk assessment framework is a progressive regulatory area. Herein, the deﬁnition of an
endocrine disruptor is given as: ‘(1) it shows an adverse effect in an intact organism or its progeny,
which is a change in the morphology, physiology, growth, development, reproduction or life span of an
organism, system or (sub)population that results in an impairment of functional capacity, an
impairment of the capacity to compensate for additional stress or an increase in the susceptibility to
other inﬂuence; (2) it has an endocrine mode of action, i.e. alters the function(s) of the endocrine
system; and (3) the adverse effect is a consequence of the endocrine mode of action’.
This piece of legislation requires a mechanistic understanding of the endocrine effects, as well as
the investigation of traditional adverse apical effects. As many of the pesticides and biocides that will
be assessed for endocrine effects during re-approval processes, the adequacy of the database will
often be uncertain. In effect, many of the substances will have a two-generation study (OECD TG416)
conducted under an old protocol, which according to the endocrine disruptor guidance is not sufﬁcient
to investigate apical effects mediated by an oestrogenic, androgenic or steroidogenic action (ECHA/
EFSA, 2018). For an example, see Figure 1.
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Adverse outcome pathways for such effects were some of the earliest to be developed, but still as of
2019, only seven AOPs for oestrogenic, androgenic, steroidogenic and thyroid action effects have been
approved or are under review. The beneﬁt of quantitative AOPs in this area is obvious, where potentially
very costly and animal-heavy studies could be waived based on appropriate early key event testing.
Other particular adverse effects have also been identiﬁed – based on human epidemiological data –
where the current animal models are not adequate, or the relevant testing has not been required. This
was exempliﬁed for Parkinson’s disease and childhood leukaemias (EFSA PPR Panel, 2017a). In
general, there is a recognition that many of the complex multifactorial human diseases are difﬁcult to
replicate in a standardised animal test. In EFSA PPR Panel (2017a), an approach was outlined for
inferring causality by developing relevant AOPs.
Another open door is in the ﬁeld of developmental neurotoxicity. The developing nervous system
might be more sensitive to exposure to certain chemicals than the adult one (OECD, 2017). For the
time being, in order to address the developmental neurotoxicity (DNT) effects of chemicals there are
two accepted guidelines, TG426 and TG443 with the DNT cohort. Across the different chemical
regulations in Europe (pesticides, biocides and industrial chemicals) and the US (pesticides), DNT
testing can be triggered based on neurotoxic effects in repeat-dose testing, known neurotoxic mode of
action or structural activity relationships.
However, the TG426 and TG443 (with DNT cohort) are often not required and thus not conducted.
For example, in Europe, until now for the almost 485 approved pesticides, the TG426 have been
available in 35 cases, whereas so far, the TG443, being a relatively newly developed guideline, has not
been applied. In total, only 200 chemicals have been tested globally (Terron and Bennekou, 2018).
Secondly, the two guidelines have signiﬁcant shortcomings, including:
• Very animal-demanding and costly
• Lack of mechanistic understanding for most of the endpoints measured
• Endpoints currently measured do not comprehensively represent, or do not reﬂect well the
complex set of endpoints of relevance to humans (e.g. cognitive functions)
• High data variability and poor data reproducibility, even for positive controls (Crofton et al.,
2004; Smirnova et al., 2014).
+: Available data
↓: Activity decreased
n.a.: No activity
Figure 1: Schematic representation of available data for four different hypothetical compounds. They
belong to the same type of compound; for example, belonging to the same type of
fungicide. All four compounds showed anti-androgenic activity in vitro. Three compounds
have an extended one-generation study showing reduced anogenital distance of male rats,
whereas the fourth compound lacks this study. The question is whether this study should
be requested for the fourth compound? In such a situation, a read-across hypothesis
supported on AOP-based testing for the effect could possibly answer the question and thus
an in vivo study would be obsolete
Holistic approach for human health risk assessment
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Consequently, consensus was reached between regulators, academic scientists and industry about
the need for an alternative DNT testing strategy that is based on a standardised in vitro battery of
tests in order to test more chemicals and inform more targeted in vivo studies (Fritsche et al., 2017).
This activity was followed up by the OECD and there are ongoing efforts to develop a guidance
document and generate data and case studies using a test battery and other NAMs in an IATA context
(Sachana et al., 2019). Also, readiness of in vitro assays for DNT testing have been assessed (Bal-Price
et al., 2018). This is an important step to achieve regulatory acceptance and facilitate changes to the
regulatory standard requirements.
A possibility in this regard, and as a step in this transition towards integrating NAMs, would be to
conduct more rigorous uncertainty analysis of the existing in vivo guideline tests. Paparella et al.
(2017) conducted a systematic uncertainty analysis of the 2-year rodent carcinogenicity bioassay. The
aim of this analysis was to deﬁne a benchmark performance of the NAM against the standard in vivo
study. Speciﬁc uncertainty analysis of the current in vivo animals along with a systematic and
quantitative uncertainty analysis of the whole risk assessment process, as well as better deﬁned
protection goals by risk managers, would generate more transparency. EFSA has taken a signiﬁcant
step with its guidance on uncertainty analysis in risk assessment (EFSA Scientiﬁc Committee, 2018);
altogether, it can be expected that it will become apparent to what extent introducing NAMS will bring
conﬁdence to a risk assessment.
3.1.4. How could regulatory systems be changed?
3.1.4.1. Classiﬁcation and labelling
One piece of legislation posing a challenge to utilising 21st century data instead of in vivo animal
data is Regulation 1272/2008 on classiﬁcation and labelling.7 Although according to the Regulation all
types of data can be used to fully determine whether a compound should be classiﬁed and labelled, a
whole data package similar to that for pesticides (Table 1) is most often necessary, where a compound
is tested up to maximum tolerated dose or above 1,000 mg/kg per day. The relevance of effects
observed at such very high doses compared to realistic human exposures is questionable (Saghir,
2015; Bus, 2017). A recent example is whether glyphosate causes cancers in rodent studies, given
that effects were sometimes observed at very high doses (Tarazona et al., 2017). Should we care
about effects observed at such dose levels, representing exposure orders of magnitude higher than
that for humans, and even so where no mechanistic explanation can be given? Perhaps it would be
more resource-efﬁcient to base classiﬁcation and labelling on broad in vitro screening, and focus on
compounds that show activity, for example endocrine disruptor activity, at doses that can be translated
to relevant human exposure levels. Figure 2 shows ToxCast chemical activity data for two compounds.
This illustrates that the second compound is far more active than the ﬁrst in different types of assays
addressing different endpoints, and to a large extent at lower doses.
From screening data, possibly linked to relevant AOPs, the point of departure could be estimated
and compared to human exposure data (Wetmore et al., 2015). This could provide a good starting
point for answering the question of whether a compound actually possesses liabilities like being a
reproductive toxicant and should therefore be appropriately classiﬁed and labelled.
7 Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classiﬁcation, labelling
and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending
Regulation (EC) No 1907/2006. OJ L 353, 31.12.2008, p. 1–1355.
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3.1.4.2. Regulatory requirements and processes
The prescriptive and mandatory standard data requirements given in many regulations are clearly
not well suited to adapt to the rapidly evolving developments of science. It would be preferable if
regulations were less prescriptive and more ﬂexible. First, ascribing speciﬁc guidelines such as the
OECD guidelines, to address a data requirement, could be changed. Rather, the data requirements
should call for a speciﬁc hazard to be addressed, for example DNT, but not prescribe which OECD
guideline should be used. Second, likewise, guidance documents complementing scientiﬁc regulatory
requirements should be less prescriptive. Examples of these less prescriptive types of guidance can be
found within the remit of medicines legislation.
The regulatory processes could also be changed. When substances are evaluated or re-evaluated,
substances belonging to the same group should be assessed at the same time, in order to facilitate
read-across between chemicals that cause toxicity through similar mechanisms. This would also allow
new developments in science to be exploited. Also, re-evaluations could also, case by case, be
targeted to those parts of the risk assessment that are of greatest concern. An example of such a
system has been outlined for pesticides (Group of Chief Scientiﬁc Advisors, 2018; SAPEA 2018). In
conclusion, the dossiers should contain sufﬁcient data to demonstrate safe use, but more ﬂexibility
should be allowed in answering ‘sufﬁciency’.
Such ﬂexibility has the inherent risk of reducing the mutual regulatory recognition between
assessments conducted under the different regulated sectors (chemical as well as geographical). This
should be avoided by harmonisation, also recognising that mutual recognition is currently rather
limited; for example, Europe would not rely solely on a recent evaluation conducted in the US
(although assessing the same data). Possibly, allowing more ﬂexibility in the various regulations would
also facilitate the opportunity to better exploit work conducted under another jurisdiction.
Figure 2: Examples of ToxCast summary data for two different chemicals, represented by screen
shots from the dashboard (https://comptox.epa.gov/dashboard/). In these summary data
only ‘hits’ are presented. ToxCast is a screening programme covering more than 700 high-
throughput assay endpoints. It is evident that the second compound showed activity in
many more of the assays compared with the compound above
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4. Conclusions
The NASEM has provided analysis and reﬂections on how to strive for a paradigm shift in risk
assessment; from risk assessment based on identiﬁcation of apical endpoints to a mechanism-based
risk assessment. Their report calls for a holistic approach in risk assessment. It clearly documents how
this shift could signiﬁcantly improve risk assessments. The next question is whether the current system
can fully realise the potential of such improvements. Several limitations and weaknesses need to be
overcome. These range from the coverage of data on which risk assessments are based, lack of
transparency, and structural, procedural and legislative issues pertaining to the current approach for
chemical risk assessment. However, there are areas where the current approach is already partly
implementing some of the new concepts, such as the identiﬁcation of endocrine disrupting chemicals.
Similarly, there are areas where the current system would obviously beneﬁt since currently there seem
to be considerable shortcomings – for example in the area of complex, multifactorial human adverse
outcomes, like metabolic disturbances, neurodevelopmental and neurodegenerative diseases. Based on
these observations, several different recommendations have been made:
– Unambiguous deﬁnition of protection goals;
– Rigorous and quantitative analysis of uncertainties in the risk assessment process;
– Harmonise risk assessment approaches across regulations and regions;
– Make data available to and analysable by the public;
– Make data requirements ﬂexible;
– Bulk similar chemicals into one assessment;
– Optimise the use of read-across;
– Do more screening;
– Speed up the development of AOPs.
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